For PatientsPrescribing InformationProvider Login
why-upneeq-herowhy-upneeq-hero-mobile

Why Upneeq could be right for your adult patients

Upneeq is the first and only FDA-approved eye drop that’s been clinically proven to quickly and safely lift low-lying eyelids. It offers a non-surgical eyelid lift, in an easy-to-use once daily eye drop.

If your patient has low-lying eyelids (acquired ptosis), Upneeq can give them a more awake-looking appearance.

Get Your Patients Started Today
BEFORE
AFTER
After
Before

Actual patient. Individual results may vary. Average upper eyelid lift with Upneeq in clinical studies was 1 mm.

Upneeq is a first-in-class treatment with a mechanism of action that lifts upper eyelids

Directly activates α-adrenergic receptors in Müller’s muscle, stimulating contraction and elevation of the upper eyelids in adults with low-lying eyelids1

In vitro functional assays demonstrate that oxymetazoline has ≈5-fold greater affinity a receptors2,3 than for α1 receptors2,3

The pharmacology of Upneeq has not been fully elucidated with respect to pharmacodynamic contribution of each receptor subtype.

Upneeq has a high completion rate in trials

97.5%

of subjects completed Upneeq clinical trials4

98%

of subjects were compliant with dosing Upneeq once daily4

2.2%

2.2% of patients in clinical trials discontinued treatment due to an adverse event4

Most common adverse reactions (incidence 1%-5%): punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache 1

Achieves significant
visual field improvement

Change from baseline in points seen in top 4 rows on LPFT (data from pooled analysis of 2 clinical trials)*4
Mean Change Chart
Upneeq (n=203)
Vehicle (n=101)
Error bars represent standard deviation of the mean change from baseline.
Why Upneeq Improvement
Upneeq demonstrated 3 times greater improvement in visual field compared to vehicle in clinical trials ( P<.01), as measured by LPFT (on Day 1 and Day 14 of treatment) 1
LPFT=Leicester Peripheral Field Test (measuring superior visual field).

*Two randomized, multicenter, double-masked, vehicle-controlled, Phase 3 studies compared once-daily Upneeq in 304 subjects with acquired blepharoptosis. Efficacy was assessed with the Leicester Peripheral Field Test (LPFT) and photographic measurement of Marginal Reflex Distance (MRD-1). There was a statistically significant difference in mean change in the LPFT from baseline after instillation of Upneeq and vehicle, with significantly greater increases in the study eye of the Upneeq group evident at the 2-hour point and maintained at the 6-hour time point. Greater MRD-1 increases were observed for the Upneeq group than the vehicle group on Day 1 at 6 hours post-dose and on Day 14 at 2 hours post-dose. 1

Introduce your patients to the eye drop that lifts.

Get Your Patients Started Today
References
1. Upneeq ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%. [Prescribing Information]. RVL Pharmaceuticals, Inc. 2024.
2. Hosten LO, Snyder C. Over-the-counter ocular decongestants in the United States - mechanisms of action and clinical utility for management of ocular redness. Clin Optom. 2020;12:95-105.
3. Haenisch B, Walstab J, Herberhold S, et al. Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010;24:729-739.
4. Slonim CB, Foster S, Jaros M, et al. Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials. JAMA Ophthalmol. 2020.

IMPORTANT SAFETY INFORMATION


What is UPNEEQ?

UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis (low-lying lids) in adults.


What warnings and precautions are associated with UPNEEQ?

  • Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions.
  • UPNEEQ is a type of medication that may affect your blood pressure. If you have heart disease, uncontrolled high or low blood pressure, or feel faint at rest or when quickly standing up, you should call your doctor if your symptoms get worse.
  • Patients with reduced blood flow to the brain or heart, or patients who experience eye or mouth dryness due to an immune system disorder (Sjögren’s syndrome), should use care when taking UPNEEQ. Call your doctor immediately if you feel your symptoms may be getting worse.
  • UPNEEQ may increase the risk of eye pressure due to fluid buildup (angle-closure glaucoma) in patients with untreated narrow-angle glaucoma. Call your doctor immediately if you feel increased pressure in your eye after using UPNEEQ.
  • Do not let the tip of the UPNEEQ vial touch your eye or any other surface. This can help prevent eye injury or contamination. Each UPNEEQ vial is for one-time use and should be discarded after being used.

What are the most common side effects of UPNEEQ?

The most common adverse reactions with UPNEEQ (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.


What should my doctor know about before prescribing me UPNEEQ?


  • Your doctor should review your full medical history before prescribing UPNEEQ.
  • UPNEEQ belongs to a class of medication (alpha-adrenergic agonists) that may affect your blood pressure. Use UPNEEQ carefully if you currently take an alpha-adrenergic agonist medication to treat heart disease or an enlarged prostate. Patients taking beta-blockers, or other medications to treat hypertension or an abnormal heartbeat, should also be careful when using UPNEEQ.
  • Patients who use a certain class of antidepressant medication (monoamine oxidase inhibitors) should also be careful when using UPNEEQ, as it may affect the way your body absorbs the medication.

These are not all of the possible side effects of UPNEEQ. Tell your doctor if you have any side effect that bothers you or does not go away. Call your doctor for medical advice about side effects.
To report side effects or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report side effects to the FDA by calling 1-800-FDA-1088 or visit www.fda.gov/medwatch.
This is a summary of the most important safety information for UPNEEQ. For more in-depth safety information, please review the full Prescribing Information for UPNEEQ.

IMPORTANT SAFETY INFORMATION


What is UPNEEQ?

UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis (low-lying lids) in adults.


What warnings and precautions are associated with UPNEEQ?

  • Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions.
  • UPNEEQ is a type of medication that may affect your blood pressure. If you have heart disease, uncontrolled high or low blood pressure, or feel faint at rest or when quickly standing up, you should call your doctor if your symptoms get worse.
  • Patients with reduced blood flow to the brain or heart, or patients who experience eye or mouth dryness due to an immune system disorder (Sjögren’s syndrome), should use care when taking UPNEEQ. Call your doctor immediately if you feel your symptoms may be getting worse.
  • UPNEEQ may increase the risk of eye pressure due to fluid buildup (angle-closure glaucoma) in patients with untreated narrow-angle glaucoma. Call your doctor immediately if you feel increased pressure in your eye after using UPNEEQ.
  • Do not let the tip of the UPNEEQ vial touch your eye or any other surface. This can help prevent eye injury or contamination. Each UPNEEQ vial is for one-time use and should be discarded after being used.

What are the most common side effects of UPNEEQ?

The most common adverse reactions with UPNEEQ (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.


What should my doctor know about before prescribing me UPNEEQ?


  • Your doctor should review your full medical history before prescribing UPNEEQ.
  • UPNEEQ belongs to a class of medication (alpha-adrenergic agonists) that may affect your blood pressure. Use UPNEEQ carefully if you currently take an alpha-adrenergic agonist medication to treat heart disease or an enlarged prostate. Patients taking beta-blockers, or other medications to treat hypertension or an abnormal heartbeat, should also be careful when using UPNEEQ.
  • Patients who use a certain class of antidepressant medication (monoamine oxidase inhibitors) should also be careful when using UPNEEQ, as it may affect the way your body absorbs the medication.

These are not all of the possible side effects of UPNEEQ. Tell your doctor if you have any side effect that bothers you or does not go away. Call your doctor for medical advice about side effects.
To report side effects or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report side effects to the FDA by calling 1-800-FDA-1088 or visit www.fda.gov/medwatch.
This is a summary of the most important safety information for UPNEEQ. For more in-depth safety information, please review the full Prescribing Information for UPNEEQ.

About UpneeqBefore and AfterWhat is Acquired PtosisResourcesContact Us
Prescribing Information
Privacy PolicyTerms of Use
FacebookTikTokInstagram

Distributed by: RVL Pharmaceuticals, Inc. Bridgewater, NJ 08807.©2024 RVL Pharmaceuticals, Inc. All rights reserved. PM-US-UPN-1709 01/25

Upneeq® is a registered trademark of RVL Pharmaceuticals, Inc.